Screener
Regeneron Pharmaceuticals REGN Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
FAQ
- What is Regeneron Pharmaceuticals's net debt / EBITDA?
- Regeneron Pharmaceuticals (REGN) reported net debt / EBITDA of 0.1× in Q2 2026.
- How has Regeneron Pharmaceuticals's net debt / EBITDA changed year-over-year?
- Regeneron Pharmaceuticals's net debt / EBITDA decreased by 65.3% year-over-year, from 0.2× to 0.1×.
- What is the long-term trend for Regeneron Pharmaceuticals's net debt / EBITDA?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's net debt / EBITDA has grown at a -22.2% compound annual growth rate (CAGR), from 0.1× to -0×.
- What does net debt / EBITDA mean?
- Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.
Ask your AI about Regeneron Pharmaceuticals's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude